The prognostic significance of Gleason scores in metastatic prostate cancer

Urologic Oncology: Seminars and Original Investigations

Volumn 32, Issue 5, 2014, Pages 707-713

  Rusthoven, Chad G ^a   Carlson, Julie A ^a   Waxweiler, Timothy V ^a   Yeh, Norman ^a   Raben, David ^a   Flaig, Thomas W ^a   Kavanagh, Brian D ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Gleason score; Histology; Metastasis; Prognosis; Prostate cancer

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

AGE; AGED; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER SPECIFIC SURVIVAL; CANCER SURVIVAL; EVALUATION STUDY; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTATIC PROSTATE CANCER; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POPULATION RESEARCH; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BLOOD LEVEL; BLOOD; CANCER GRADING; CANCER REGISTRY; DISEASE FREE SURVIVAL; KAPLAN MEIER METHOD; METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; PROSTATIC NEOPLASMS; TIME; TREATMENT OUTCOME; UNITED STATES; UTILIZATION;

AGED; DISEASE-FREE SURVIVAL; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM METASTASIS; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SEER PROGRAM; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 84902491054     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2014.01.004     Document Type: Article

References (27)

1. Pierorazio P.M., Walsh P.C., Partin A.W., Epstein J.I. Prognostic Gleason grade grouping: data based on the modified Gleason scoring system. Br J Urol Int 2013, 111:753-760.
2. Jackson W., Hamstra D.A., Johnson S., et al. Gleason pattern 5 is the strongest pathologic predictor of recurrence, metastasis, and prostate cancer-specific death in patients receiving salvage radiation therapy following radical prostatectomy. Cancer 2013, 119:3287-3294.
3. Stark J.R., Perner S., Stampfer M.J., et al. Gleason score and lethal prostate cancer: does 3+4 = 4+3?. J Clin Oncol 2009, 27:3459-3464.
4. Stock R.G., Cesaretti J.A., Hall S.J., Stone N.N. Outcomes for patients with high-grade prostate cancer treated with a combination of brachytherapy, external beam radiotherapy and hormonal therapy. Br J Urol Int 2009, 104:1631-1636.
5. Glass T.R., Tangen C.M., Crawford E.D., Thompson I. Metastatic carcinoma of the prostate: identifying prognostic groups using recursive partitioning. J Urol 2003, 169:164-169.
6. Hussain M., Tangen C.M., Higano C., et al. Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). J Clin Oncol 2006, 24:3984-3990.
7. Loblaw D.A., Virgo K.S., Nam R., et al. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol 2007, 25:1596-1605.
8. Halabi S., Small E.J., Kantoff P.W., et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol 2003, 21:1232-1237.
9. Nakabayashi M., Hayes J., Taplin M.E., et al. Clinical predictors of survival in men with castration-resistant prostate cancer: evidence that Gleason score 6 cancer can evolve to lethal disease. Cancer 2013, 119:2990-2998.
10. Smaletz O., Scher H.I., Small E.J., et al. Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. J Clin Oncol 2002, 20:3972-3982.
11. Benaim E.A., Pace C.M., Roehrborn C.G. Gleason score predicts androgen independent progression after androgen deprivation therapy. Eur Urol 2002, 42:12-17.
12. Epstein J.I., Allsbrook W.C., Amin M.B., Egevad L.L., Committee I.G. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason grading of prostatic carcinoma. Am J Surg Pathol 2005, 29:1228-1242.
13. SEER program coding and staging manual 2004, revision 1, 〈〉[accessed 3.9.13]. http://www.Seer.Cancer.Gov/tools/codingmanuals/historical.Html.
14. AJCC cancer staging manual 2011, Springer, New York, NY. 7th ed.
15. Nanda A., Chen M.-H., Renshaw A.A., D'Amico A.V. Gleason pattern 5 prostate cancer: further stratification of patients with high-risk disease and implications for future randomized trials. Int J Radiat Oncol Biol Phys 2009, 74:1419-1423.
16. Serni S., Masieri L., Minervini A., Lapini A., Nesi G., Carini M. Cancer progression after anterograde radical prostatectomy for pathologic Gleason score 8 to 10 and influence of concomitant variables. Urology 2006, 67:373-378.
17. Bittner N., Merrick G.S., Butler W.M., Galbreath R.W., Adamovich E., Wallner K.E. Gleason score 7 prostate cancer treated with interstitial brachytherapy with or without supplemental external beam radiation and androgen deprivation therapy: is the primary pattern on needle biopsy prognostic?. Brachytherapy 2013, 12:14-18.
18. Chan T.Y., Partin A.W., Walsh P.C., Epstein J.I. Prognostic significance of Gleason score 3+4 versus Gleason score 4+3 tumor at radical prostatectomy. Urology 2000, 56:823-827.
19. Lim S., Kim K., Shin T.-Y., et al. Gleason 5+4 has worse oncological and pathological outcomes compared with Gleason 4+5: significance of Gleason 5 pattern. Ann Surg Oncol 2013, 20:3127-3132.
20. Billis A., Guimaraes M.S., Freitas L.L., Meirelles L., Magna L.A., Ferreira U. The impact of the 2005 International society of urological pathology consensus conference on standard Gleason grading of prostatic carcinoma in needle biopsies. J Urol 2008, 180:548-552. [discussion 552-3].
21. Hernandez D.J., Nielsen M.E., Han M., et al. Natural history of pathologically organ-confined (pT2), Gleason score 6 or less, prostate cancer after radical prostatectomy. Urology 2008, 72:172-176.
22. Epstein J.I., Feng Z., Trock B.J., Pierorazio P.M. Upgrading and downgrading of prostate cancer from biopsy to radical prostatectomy: incidence and predictive factors using the modified Gleason grading system and factoring in tertiary grades. Eur Urol 2012, 61:1019-1024.
23. Sabolch A., Feng F.Y., Daignault-Newton S., et al. Gleason pattern 5 is the greatest risk factor for clinical failure and death from prostate cancer after dose-escalated radiation therapy and hormonal ablation. Int J Radiat Oncol Biol Phys 2011, 81:e351-e360.
24. Cheng L., Davidson D.D., Lin H., Koch M.O. Percentage of Gleason pattern 4 and 5 predicts survival after radical prostatectomy. Cancer 2007, 110:1967-1972.
25. Humphreys M.R., Fernandes K.A., Sridhar S.S. Impact of age at diagnosis on outcomes in men with castrate-resistant prostate cancer (CRPC). J Cancer 2013, 4:304-314.
26. Irshad S., Bansal M., Castillo-Martin M., et al. A molecular signature predictive of indolent prostate cancer. Sci Transl Med 2013, 5. (202ra122).
27. Karnes R.J., Bergstralh E.J., Davicioni E., et al. Validation of a genomic classifier that predicts metastasis following radical prostatectomy in an at risk patient population. J Urol 2013, 190:2047-2053.